We’re building a web-based application for architects that speeds up their design workflow and makes high-quality visualization accessible to a wider audience. We have experienced rapid growth in recent months and we are hiring to further scale the company. We have customers in over 120 different countries, who collectively have generated over 6 million visualizations on our platform since 2023.

We're building AI-powered systems to make hospital operating rooms safer and more efficient.

We're building truly autonomous hospital operations, starting with labor optimization. We hit 8 figures in revenue in 2 years and closed a Series A last month.

Vitalize is building software that helps health systems optimize how they schedule and deploy their nursing workforce. Our product replaces legacy systems as the system-of-record for all nursing schedules across the enterprise (touching THOUSANDS of staff per customer).

At VivaCity, we make cities smarter, safer, and more sustainable. We have over 5,000 AI sensors around the world, gathering real-time anonymous data on transport modes, traffic flow, and travel patterns. This is used to gather actionable insights to support strategic decisions to improve the global transport network.

We're building edge AI and a data platform for high-throughput, high-fidelity analysis of fruit crops to get this $1T industry ready for the future of farming. We operate in orchards in vineyards around the world.

Vividly is a Series A startup aiming to transform the efficiencies of CPG finance and sales teams by moving them from Excel to the Vividly platform. The team is focused on adding new features to the analytics portion of their product, including work around generative AI and pricing optimization.

At our Boston Innovation Center, we're delivering an integrated platform, award-winning products and the industry's first artificial intelligence for the smart home.

Vivodyne is a pre-series-A startup spun off from U. Penn. You'll be working on the web interface that scientists use to define studies that our robots will then perform by culturing, treating, and imaging human organoid tissues.

We are a later stage startup and are a pioneer in the use of clinically backed AI algorithms and machine learning to increase the speed of diagnosis and care across 1,500+ hospitals and health systems in the U.S. and Europe.